Details for Patent: 10,351,517

Which drugs does patent 10,351,517 protect, and when does it expire?

Patent 10,351,517 protects SUNOSI and is included in one NDA.

This patent has twenty patent family members in fifteen countries.

Summary for Patent: 10,351,517

Title:	Treatment of sleep-wake disorders
Abstract:	This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the ox en atom.
Inventor(s):	Ahnaou; Abdallah (Berchem, BE), Drinkenburg; Wilhelmus H. I. M. (Molenschot, NL), Palumbo; Joseph (Saint Davids, PA), Sporn; Jonathan (Princeton, NJ)
Assignee:	SK Biopharmaceuticals Co., Ltd. (Seongnam-si, Gyeonggi-do, KR)
Application Number:	15/433,660
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,351,517
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 10,351,517

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-001	Jun 17, 2019		RX	Yes	No						TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-002	Jun 17, 2019		RX	Yes	Yes						TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)

International Family Members for US Patent 10,351,517

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006254899
Brazil	PI0613697
Canada	2611713
China	101217949